CRC Research Update — July 24, 2026
Today's colorectal cancer research highlights
msi-h
A collection of 52 issues
MSI-H/dMMR Prevalence Documented in Japanese CRC Registry
Skip to content
The CRC Digest
MSI-H/dMMR Prevalence Documented in Japanese CRC Registry
A multicenter study of 1,464 Japanese patients with primary colorectal cancer enrolled from April 2024 to March 2025 investigated the frequency and features of MSI-H/dMMR tumors to support personalized treatment strategies. (Annals of Gastroenterological
CRISPR Screens Reveal How MSI-H Tumors Depend on WRN Helicase
Skip to content
The CRC Digest
◇ RESEARCH
CRISPR Screens Reveal How MSI-H Tumors Depend on WRN Helicase
Genome-wide CRISPR screens identified SMARCAL1 as a key modulator of WRN dependency in MSI-H colorectal cancer, with loss of SMARCAL1 rendering cells resistant to the WRN inhibitor HRO761. The findings shed light on
First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer
A meta-analysis of phase III trials confirms immune checkpoint inhibitors show superior progression-free and overall survival compared to standard chemotherapy as first-line treatment for patients with MSI-H or dMMR metastatic disease. (J
CRC Research Update — July 20, 2026
Today's colorectal cancer research highlights
CRC Research Update — July 19, 2026
Today's colorectal cancer research highlights
Single-section PMS2/MSH6 double immunohistochemistry shows promise as screening tool for mismatch repair deficiency
Skip to content
The CRC Digest
◇ RESEARCH
Single-section PMS2/MSH6 double immunohistochemistry shows promise as screening tool for mismatch repair deficiency
A study of 794 colorectal and endometrial cancer cases evaluated whether a single-section test could accurately identify deficient mismatch repair (dMMR) status. (Human Pathology)
This content is informational only
CRC Research Update — July 17, 2026
Today's colorectal cancer research highlights
DR5/Ligase 3 feedback loop drives immunogenicity in dMMR/MSI CRC
Skip to content
The CRC Digest
DR5/Ligase 3 feedback loop drives immunogenicity in dMMR/MSI CRC
Preclinical study investigated why dMMR/MSI colorectal cancers are intrinsically immunogenic and why some do not respond or develop resistance to immune checkpoint inhibitors. (Gastroenterology)
This content is informational only and does not
CRC Research Update — July 16, 2026
Today's colorectal cancer research highlights